Dec 7, 2025 · In patients with follicular lymphoma being treated in the third-line setting or later, liso-cel therapy is associated with durable responses.

Jun 27, 2023 · New research suggests that lisocabtagene maraleucel (liso-cel) is a potential treatment option for relapsed or refractory CLL/SLL.

Jan 8, 2024 · Liso-cel is cost-effective as second-line therapy for diffuse large B-cell lymphoma, according to researchers.

Jul 31, 2024 · New-onset ICANS from days 8 to 14 after CAR T-cell infusion occurred in 9.3% of patients overall, 19% of axi-cel recipients, 9% of liso-cel recipients, and 1% of tisa-cel recipients (P <.0001).

Key Takeaways Glofitamab, odronextamab, and epcoritamab are anti-CD20 bispecific antibodies that simultaneously bind to malignant B cells and circulating T cells. Epcoritamab, which was approved ...

Dec 10, 2023 · Second-line lisocabtagene maraleucel (liso-cel) can produce durable complete responses (CRs) in patients with large B-cell lymphoma (LBCL) who are not eligible for transplant, …

Jun 30, 2025 · The FDA has approved updated labels for Breyanzi and Abecma, removing the REMS programs and reducing certain restrictions.

Jun 18, 2024 · Trials presented at ASCO 2024 highlighted advances in Hodgkin lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and NK/T-cell lymphoma.

Apr 9, 2024 · Liso-Cel for MCL PDUFA date: May 31, 2024 Bristol Myers Squibb is also seeking approval for liso-cel to treat relapsed or refractory MCL.

Dec 11, 2020 · A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL. The …